Metabolic disorders affecting the liver and heart : Therapeutic efficacy of miRNA-based therapies?
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..
Liver and heart disease are major causes of death worldwide. It is known that metabolic alteration causing type 2 diabetes (T2D) and Nonalcoholic fatty liver (NAFLD) coupled with a derangement in lipid homeostasis, may exacerbate hepatic and cardiovascular diseases. Some pharmacological treatments can mitigate organ dysfunctions but the important side effects limit their efficacy leading often to deterioration of the tissues. It needs to develop new personalized treatment approaches and recent progresses of engineered RNA molecules are becoming increasingly viable as alternative treatments. This review outlines the current use of antisense oligonucleotides (ASOs), RNA interference (RNAi) and RNA genome editing as treatment for rare metabolic disorders. However, the potential for small non-coding RNAs to serve as therapeutic agents for liver and heart diseases is yet to be fully explored. Although miRNAs are recognized as biomarkers for many diseases, they are also capable of serving as drugs for medical intervention; several clinical trials are testing miRNAs as therapeutics for type 2 diabetes, nonalcoholic fatty liver as well as cardiac diseases. Recent advances in RNA-based therapeutics may potentially facilitate a novel application of miRNAs as agents and as druggable targets. In this work, we sought to summarize the advancement and advantages of miRNA selective therapy when compared to conventional drugs. In particular, we sought to emphasise druggable miRNAs, over ASOs or other RNA therapeutics or conventional drugs. Finally, we sought to address research questions related to efficacy, side-effects, and range of use of RNA therapeutics. Additionally, we covered hurdles and examined recent advances in the use of miRNA-based RNA therapy in metabolic disorders such as diabetes, liver, and heart diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:201 |
|---|---|
| Enthalten in: |
Pharmacological research - 201(2024) vom: 01. März, Seite 107083 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
La Sala, Lucia [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.phrs.2024.107083 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367988607 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367988607 | ||
| 003 | DE-627 | ||
| 005 | 20240304232420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240204s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2024.107083 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM367988607 | ||
| 035 | |a (NLM)38309383 | ||
| 035 | |a (PII)S1043-6618(24)00027-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a La Sala, Lucia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolic disorders affecting the liver and heart |b Therapeutic efficacy of miRNA-based therapies? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Liver and heart disease are major causes of death worldwide. It is known that metabolic alteration causing type 2 diabetes (T2D) and Nonalcoholic fatty liver (NAFLD) coupled with a derangement in lipid homeostasis, may exacerbate hepatic and cardiovascular diseases. Some pharmacological treatments can mitigate organ dysfunctions but the important side effects limit their efficacy leading often to deterioration of the tissues. It needs to develop new personalized treatment approaches and recent progresses of engineered RNA molecules are becoming increasingly viable as alternative treatments. This review outlines the current use of antisense oligonucleotides (ASOs), RNA interference (RNAi) and RNA genome editing as treatment for rare metabolic disorders. However, the potential for small non-coding RNAs to serve as therapeutic agents for liver and heart diseases is yet to be fully explored. Although miRNAs are recognized as biomarkers for many diseases, they are also capable of serving as drugs for medical intervention; several clinical trials are testing miRNAs as therapeutics for type 2 diabetes, nonalcoholic fatty liver as well as cardiac diseases. Recent advances in RNA-based therapeutics may potentially facilitate a novel application of miRNAs as agents and as druggable targets. In this work, we sought to summarize the advancement and advantages of miRNA selective therapy when compared to conventional drugs. In particular, we sought to emphasise druggable miRNAs, over ASOs or other RNA therapeutics or conventional drugs. Finally, we sought to address research questions related to efficacy, side-effects, and range of use of RNA therapeutics. Additionally, we covered hurdles and examined recent advances in the use of miRNA-based RNA therapy in metabolic disorders such as diabetes, liver, and heart diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ASOs | |
| 650 | 4 | |a Druggable targets | |
| 650 | 4 | |a Heart diseases | |
| 650 | 4 | |a Liver dysfunction | |
| 650 | 4 | |a MiRNAs | |
| 650 | 4 | |a ModRNAs | |
| 650 | 4 | |a RNA therapy | |
| 650 | 4 | |a aspirin (PubChem CID: 2244) | |
| 650 | 4 | |a bevasiranib (PubChem CID: 70695615) | |
| 650 | 4 | |a cobomarsen (PubChem CID: 126480232) anti miR-155 | |
| 650 | 4 | |a fomivirsen (PubChem CID: 129651696) | |
| 650 | 4 | |a inclisiran (PubChem CID: 126480325) | |
| 650 | 4 | |a miR-122 (PubChem CID: 801592) | |
| 650 | 4 | |a neomycin (PubChem CID: 8378) | |
| 650 | 4 | |a patisiran (PubChem CID: 483928509) | |
| 650 | 4 | |a risdiplam (PubChem CID: 163321874) | |
| 650 | 4 | |a s-acetyl-cysteine (PubChem CID: 10130120) | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a Oligonucleotides, Antisense |2 NLM | |
| 700 | 1 | |a Carlini, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Conte, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Macas-Granizo, Maria Belen |e verfasserin |4 aut | |
| 700 | 1 | |a Afzalpour, Elham |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Delgado, Jimmy |e verfasserin |4 aut | |
| 700 | 1 | |a D'Anzeo, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Pedretti, Roberto F E |e verfasserin |4 aut | |
| 700 | 1 | |a Naselli, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Pontiroli, Antonio E |e verfasserin |4 aut | |
| 700 | 1 | |a Cappato, Riccardo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological research |d 1992 |g 201(2024) vom: 01. März, Seite 107083 |w (DE-627)NLM012597384 |x 1096-1186 |7 nnns |
| 773 | 1 | 8 | |g volume:201 |g year:2024 |g day:01 |g month:03 |g pages:107083 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phrs.2024.107083 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 201 |j 2024 |b 01 |c 03 |h 107083 | ||